Phase II Trial of cdk Inhibitor SCH 727965 in Multiple Myeloma (P2C MC0888, NCI 8288).

Trial Profile

Phase II Trial of cdk Inhibitor SCH 727965 in Multiple Myeloma (P2C MC0888, NCI 8288).

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2014

At a glance

  • Drugs Dinaciclib (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Feb 2013 New source identified and integrated (Mayo Clinic: 08-004470)
    • 19 Dec 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top